Mimi C. Tan

Mimi C. Tan

Auto-generated profile, based on publicly available information

Mimi C. Tan

Section of Gastroenterology and Hepatology, Department of Medicine Baylor College of Medicine Houston Texas USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
TQTimothy Quang
Timothy Quang
RSRichard A. Schwarz
Richard A. Schwarz
SDSanford M. Dawsey
Sanford M. Dawsey
MTMimi C. Tan
Mimi C. Tan
KPKalpesh Patel
Kalpesh Patel
RRRebecca Richards-Kortum
Rebecca Richards-Kortum

26 May 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MTMimi C. Tan
Mimi C. Tan
NMNabil Mansour
Nabil Mansour
DWDonna L. White
Donna L. White
ASAmy Sisson
Amy Sisson
HEHashem B. El‐Serag
Hashem B. El‐Serag
ATAaron P. Thrift
Aaron P. Thrift

3 January 2020 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MTMimi C. Tan
Mimi C. Tan
NMNiharika Mallepally
Niharika Mallepally
YLYan Liu
Yan Liu
HEHashem B. El-Serag
Hashem B. El-Serag
ATAaron P. Thrift
Aaron P. Thrift
OBJECTIVES: The risk of noncardia gastric cancer is increased in the presence of gastric intestinal metaplasia. We aimed to identify demographic and lifestyle factors independently associated with the risk of gastric intestinal metaplasia. METHODS: We used data from a cross-sectional study of patients attending primary care and endoscopy clinics at the Michael E. DeBakey VA Medical Center in Houston, Texas, between February 2008 and August 2013. All patients completed standardized questionnaires and underwent endoscopy with gastric mapping biopsies. Gastric intestinal metaplasia cases included patients with intestinal metaplasia on any noncardia gastric biopsy; we defined extensive gastric intestinal metaplasia as antrum and corpus involvement. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) using multivariate logistic regression models. RESULTS: We identified 423 cases with gastric intestinal metaplasia and 1,796 controls without gastric intestinal metaplasia. Older age (vs <60 years: 60–69 years AdjOR, 1.50; 95% CI, 1.17–1.93; ≥70 years AdjOR, 2.12; 95% CI, 1.48–3.04), male sex (AdjOR, 2.76; 95% CI, 1.50–5.10), nonwhite race/ethnicity (vs non-Hispanic white: Hispanic, AdjOR, 2.66; 95% CI, 1.89–3.76; black, AdjOR, 2.36; 95% CI, 1.85–3.02), and current smoking status (AdjOR, 1.78; 95% CI, 1.29–2.48) were independently associated with gastric intestinal metaplasia. These risk factors remained statistically significantly associated with gastric intestinal metaplasia after adjusting for Helicobacter pylori infection, and their effect sizes were larger for associations with extensive gastric intestinal metaplasia compared with focal gastric intestinal metaplasia. DISCUSSION: Older age, male sex, nonwhite race/ethnicity, and current smoking status were the nonendoscopic factors independently associated with gastric intestinal metaplasia in a predominantly nonimmigrant US population.

29 June 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MTM. C. Tan
M. C. Tan
HEH. B. El‐Serag
H. B. El‐Serag
XYX. Yu
X. Yu
ATAaron P. Thrift
Aaron P. Thrift
Summary: Background: Proton pump inhibitors (PPIs) and histamine‐2 receptor antagonists (H2RAs) may reduce the risk of oesophageal adenocarcinoma (OAC) in Barrett's oesophagus; however, current epidemiologic studies are inconclusive.Aim: To evaluate the independent effects of PPIs and H2RAs on risk of OAC in patients with Barrett's oesophagus.Methods: We conducted a nested case‐control study of male veterans diagnosed with Barrett's oesophagus. Cases with incident OAC were matched by incidence density sampling on birth year and Barrett's diagnosis date to controls with Barrett's oesophagus who did not develop OAC. We identified prescription medication usage 1 year prior to Barrett's oesophagus diagnosis to 3 months prior to the OAC diagnosis. Odds ratios (OR) and 95% CI were estimated using conditional logistic regression.Results: Compared with 798 controls, the 300 cases were less likely to use PPIs (90.0% vs 94.5%, P = 0.01) and H2RAs (19.7% vs 25.7%, P = 0.04). In the multivariable model including the use of statins, H2RAs, aspirin and nonsteroidal anti‐inflammatory drugs, PPI use was associated with 41% lower risk of OAC (OR 0.59, 95% CI 0.35‐0.99). While risk reduction of OAC was stronger for high‐dose PPIs (omeprazole daily dose >40 mg, adjusted OR 0.11, 95% 0.04‐0.36), we did not find a dose‐response relationship with PPI duration (P trend = 0.45). Likewise, H2RA use was independently associated with 30% lower risk of OAC (OR 0.70, 95% CI 0.50‐0.99).Conclusion: Use of PPIs and H2RAs among patients with Barrett's oesophagus are associated with lower risk of OAC. Further clinical trials are needed to confirm this possible chemopreventive effect.

14 November 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
TNTheresa H. Nguyen
Theresa H. Nguyen
NMNiharika Mallepally
Niharika Mallepally
THTariq Hammad
Tariq Hammad
YLYan Liu
Yan Liu
ATAaron P. Thrift
Aaron P. Thrift
MTMimi C. Tan
Mimi C. Tan
Background Helicobacter pylori infection is an established causal factor for non-cardia gastric cancer. H. pylori negative gastric cancer prevalence among US patients is unclear. Methods This retrospective cohort study examined H. pylori prevalence among consecutive patients with incident non-cardia gastric adenocarcinoma at the Houston VA Hospital (11/2007–10/2018). H. pylori positivity was defined by H. pylori on histopathology, positive antibody serology, stool antigen, or urea breath testing. We examined for trends in H. pylori negative gastric cancer based on year of diagnosis. Associations between histopathologic and cancer-related outcomes with H. pylori positivity were determined using regression models. Results Of 91 patients with gastric adenocarcinoma, most were men (N = 87, 95.6%), black (N = 47, 51.6%), with mean age at diagnosis of 68.0 years (SD 10.8). In addition to gastric cancer biopsy histopathology, 74 patients (81.3%) had ≥ 1 testing for H. pylori, including antibody serology (n = 34), non-cancer gastric biopsy histopathology (n = 63), or stool antigen (n = 1). The overall prevalence of H. pylori infection was 38.5% and 45.9% among patients with ≥ 2 H. pylori tests. The proportions of H. pylori positive gastric cancer decreased from 50.0% (2007–2010) to 43.4% (2011–2014) and 29.3% (2015–2018) (p = 0.096). Active/acute gastritis (adjOR 3.74), atrophic gastritis (adjOR 15.30), and gastric intestinal metaplasia (adjOR 3.65) were associated with H. pylori positive gastric cancer. Discussion The prevalence of H. pylori infection among patients with non-cardia gastric adenocarcinoma is relatively low (38.5–45.9%) and decreasing over time. This finding suggests there may be other important causal factors apart from H. pylori for gastric adenocarcinoma.

15 December 2021 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MTMimi C. Tan
Mimi C. Tan
TJTaher Jamali
Taher Jamali
TNTheresa H. Nguyen
Theresa H. Nguyen
AGAmy Galvan
Amy Galvan
RSRobert J. Sealock
Robert J. Sealock
ATAaron P. Thrift
Aaron P. Thrift
INTRODUCTION: Several US subgroups have increased risk of gastric cancer and gastric intestinal metaplasia (GIM) and may benefit from targeted screening. We evaluated demographic and clinical risk factors for GIM and examined the interaction between race/ethnicity and birthplace on GIM risk. METHODS: We identified patients who had undergone esophagogastroduodenoscopy with gastric biopsy from 3/2006–11/2016 using the pathology database at a safety net hospital in Houston, Texas. Cases had GIM on ≥1 gastric biopsy histopathology, whereas controls lacked GIM on any biopsy. We estimated odds ratios and 95% confidence intervals (CI) for associations with GIM risk using logistic regression and developed a risk prediction model of GIM risk. We additionally examined for associations using a composite variable combining race/ethnicity and birthplace. RESULTS: Among 267 cases with GIM and 1,842 controls, older age (vs 60 years adjOR 4.58; 95% CI 2.61–8.03), Black race (vs non-Hispanic White: adjOR 2.17; 95% CI 1.31–3.62), Asian race (adjOR 2.83; 95% CI 1.27–6.29) , and current smoking status (adjOR 2.04; 95% CI 1.39–3.00) were independently associated with increased GIM risk. Although non-US-born Hispanics had higher risk of GIM (vs non-Hispanic White: adjOR 2.10; 95% CI 1.28–3.45), we found no elevated risk for US-born Hispanics (adjOR 1.13; 95% CI 0.57–2.23). The risk prediction model had area under the receiver operating characteristic of 0.673 (95% CI 0.636–0.710) for discriminating GIM. DISCUSSION: We found that Hispanics born outside the United States were at increased risk of GIM, whereas Hispanics born in the United States were not, independent of Helicobacter pylori infection. Birthplace may be more informative than race/ethnicity when determining GIM risk among US populations.